Saturday 17 October 2026
Export XRTX’s income statement to Excel — free account
XORTX Therapeutics Inc.
XRTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 10.5% and free cash flow fell 318.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.24
0.18
−12.68%
Follow XRTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(94.63%) | (98.00%) | (137.45%) | (99.24%) | |
| (58.35%) | (78.38%) | (98.03%) | (83.78%) | ||
ROIC |
(258.95%) | (166.80%) | (188.43%) | (54.27%) | |
Return on Tangible Assets |
(335.24%) | (379.97%) | 2,714.62% | (212.77%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.08) | (2.98) | (1.93) | (3.26) | |
Free Cash Flow |
(2.99) | (2.82) | (2.68) | (5.28) | |
Capital Expenditures |
(0.03) | (0.06) | (0.06) | (0.18) | |
| Other line items | |||||
Cash ROIC |
(94.33%) | (95.76%) | (174.83%) | (81.21%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.52 | 1.04 | 0.95 | 1.36 | |
Depreciation/Fixed assets |
1.83 | 3.02 | 7.61 | 0.00 | |
Capex/Depreciation |
(0.32) | (0.49) | (0.50) | (1.73) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.04) | (2.92) | (1.89) | (3.15) | |
Capex per Share |
(0.04) | (0.06) | (0.04) | (0.11) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates